Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

被引：4
|
作者：
Chow, Laura Quan Man
Mehra, Ranee
Haddad, Robert I.
Mahipal, Amit
Weiss, Jared
Berger, Raanan
Eder, Joseph Paul
Burtness, Barbara
Tahara, Makoto
Keam, Bhumsuk
Le, Dung T.
Muro, Kei
Geva, Ravit
Chung, Hyun Cheol
Lin, Chia-Chi
Ayers, Mark
Aurora-Garg, Deepti
Lunceford, Jared K.
Cheng, Jonathan D.
Seiwert, Tanguy Y.
机构：
[1] Seattle Canc Care Alliance, Seattle, WA USA
[2] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA
[6] Sheba Med Ctr, Tel Hashomer, Israel
[7] Yale Canc Ctr, New Haven, CT USA
[8] Natl Canc Ctr Hosp East, Chiba, Japan
[9] Seoul Natl Univ Hosp, Seoul, South Korea
[10] Johns Hopkins Univ, Baltimore, MD USA
[11] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[12] Sourasky Med Ctr, Tel Aviv, Israel
[13] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[14] Natl Taiwan Univ Hosp, Taipei, Taiwan
[15] Merck & Co Inc, Kenilworth, NJ USA
[16] Univ Chicago, Chicago, IL 60637 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.6010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6010
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial
    Cohen, E. E.
    Harrington, K. J.
    Le Tourneau, C.
    Dinis, J.
    Licitra, L.
    Ahn, M-J.
    Soria, A.
    Machiels, J-P.
    Mach, N.
    Mehra, R.
    Burtness, B.
    Wang, Y.
    Tuozzo, A. J.
    Swaby, R.
    Soulieres, D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC)
    Sun, Lova
    Cohen, Roger B.
    Colevas, A. Dimitrios
    ORAL ONCOLOGY, 2024, 158
  • [3] Platinum/taxane/pembrolizumab vs Platinum/5-fluorouracil/pembrolizumab in recurrent/metastatic Head and Neck Squamous Cell Carcinoma (r/m HNSCC)
    Sun, L.
    Cohen, R.
    Colevas, A. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E34 - E35
  • [4] Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC).
    Sun, Lova
    Cohen, Roger B.
    Colevas, A. Dimitrios Dimitrios
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Evaluation of systemic inflammatory response (SIR) markers in recurrent or metastatic head and neck squamous cell carcinoma (r/m HNSCC)
    Pogorzelski, M.
    Hilser, T.
    Ting, S.
    Vossebein, I
    Gauler, T. C.
    Abendroth, A.
    Lang, S.
    Stuck, B.
    Abu-Jawad, J.
    Stuschke, M.
    Schmid, K. W.
    Schuler, M.
    Kasper, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 307 - 308
  • [6] Clinical biomarkers as predictors of immunotherapy (IT) benefit in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pt)
    Hernando-Calvo, A.
    Mirallas, O.
    Marmolejo, D.
    Felip, E.
    Villacampa Javierre, G.
    Garralda, E.
    Gutierrez, R.
    Feliu, B.
    Martinez, S.
    Dienstmann, R.
    Brana, I.
    ANNALS OF ONCOLOGY, 2019, 30 : 25 - 25
  • [7] The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC).
    Scheff, Nicole N.
    Nilsen, Marci Lee
    Li, Jinhong
    Harris, Alexandria L.
    Swartz, Andrew
    Hsieh, Ronan Wenhan
    Anderson, Jennifer Lynn
    Ferris, Robert L.
    Menk, Ashley
    Delgoffe, Greg M.
    Zandberg, Dan Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Analysis of immune and genomic landscapes of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with pembrolizumab in the INSPIRE study
    Bernal, M. Oliva
    Lien, S.
    Wang, B. X.
    Yang, S. C.
    Spreafico, A.
    Jang, R.
    Elston, S.
    Jennings, S.
    Jiang, H.
    Haibe-Kains, B.
    Pugh, T.
    Ohashi, P.
    Siu, L. L.
    Hansen, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] Pembrolizumab and afatinib for recurrent or metastatic head and neck squamous cell carcinoma
    Kao, H-F.
    Hong, R-L.
    ANNALS OF ONCOLOGY, 2018, 29 : 379 - 379
  • [10] Pembrolizumab and afatinib for recurrent or metastatic head and neck squamous cell carcinoma
    Kao, Hsiang-Fong
    Huang, Huai-Cheng
    Liao, Bin-Chi
    Hong, Ruey-Long
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
12345